VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER) (DOPER)

  • STATUS
    Recruiting
  • End date
    Mar 20, 2024
  • participants needed
    400
  • sponsor
    Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Updated on 4 October 2022
remission
methotrexate
mercaptopurine
vedolizumab
azathioprine

Summary

Descriptive : A 12-months multicenter, observational, prospective cohort study. Population : IBD patients under stable clinical and biological remission will be proposed to switch from the IV vedolizumab to the SC vedolizumab as part of routine care. All consecutive IBD patients in IBD centers participating in the study will be proposed to participate in the study during their regular outpatients' visits.

Objectives : The primary objective of DOPER study is to describe SC vedolizumab persistence after switching from IV vedolizumab to SC vedolizumab at month 12.

Description

Number of patients : 400 patients in approximatively 31 sites in France. Recrutment period : The trial duration for each patient will be 1 year main. Endpoint : The primary endpoint is to assess the rate of persistence of SC vedolizumab at month 12 after switching from IV vedolizumab to SC vedolizumab.

Secondary Endpoint :

  • Percentage of clinical remission at months 3 and 12, defined as a Partial Mayo Score (PMS) <2 with each sub-score (stool frequency, rectal bleeding, and physician rating of disease activity) of 1 or less for UC patients and as a Harvey Bradshaw Index (HBI) score ≤4 for CD patients
  • Percentage of steroid free clinical remission at month 12
  • Percentage of biological remission rates (defined as fecal calprotectin <250 μg/g and C-Reactive-Protein (CRP) <5 mg/L) at month 12
  • Percentage of Patient-Reported Outcome 2 (PRO-2, defined as stool frequency and rectal bleeding for UC and stool frequency and abdominal pain for CD) response and remission at month 12
  • Percentage of clinical relapse free rates at month 12
  • Percentage of loss of response rates at month 12
  • Mean change from baseline in PMS or HBI, CRP and fecal calprotectin compared to month 12
  • Percentage of patients who switch back to previous IV vedolizumab therapy at month 12after switching from IV vedolizumab to SC vedolizumab
  • Proportion of patients with positive antibodies (VDZ, ANA) comparing therapy with IV and SC vedolizumab
  • Persistence of SC vedolizumab at month 12 in patients previously treated by IV vedolizumab every 4 weeks, compared to patients treated by IV vedolizumab every 8 weeks
  • Twelve-month cumulative surgery rates
  • Hospitalization rate at month 12
  • Cumulative infection rate at month 12
  • Cumulative injection reactions at month 12
  • Cumulative adverse events (AEs) rate at month 12
  • Comparison between incidence of specific anti-drug antibodies and incidence of AEs

Details
Condition Inflammatory Bowel Diseases
Treatment Subcutaneous vedolizumab
Clinical Study IdentifierNCT05158517
SponsorGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female subjects who are more than 18 years of age, on the day of signing informed consent
Documented diagnosis of IBD, established on the basis of standard clinical, endoscopic and/or histological criteria
CD or UC remission defined per clinical assessment as a Harvey Bradshaw Index (HBI) score ≤4 for CD patients and a Partial Mayo Score (PMS) < 2 with each sub-score of 1 or less for UC and/or according to ECCO classification within previous 3 months
Currently treated with IV vedolizumab
Patients agreeing to switch from IV to SC formulation
Receiving or not the concomitant following drugs (but must remain on stable dose for 12 weeks)
Oral 5-aminosalicylates (5ASA) compounds or rectal formulations of 5ASA provided the dose to be stable at least 4 weeks before switching
Azathioprine, 6-Mercaptopurine or methotrexate provided the dose has been stable for 4 weeks prior to inclusion • Each patient is required to provide written informed consent in order to be included in the study

Exclusion Criteria

Current use of adalimumab, infliximab, golimumab or ustekinumab
Current use of JAK inhibitors or S1P modulators
Current use of steroids or within the last three months for IBD
Treatment with any investigational agent in the past 30 days or five half-lives prior to the screening visit (whichever is longer)
Active clinically significant infection or HIV, Hep B, Hep C, untreated tuberculosis
Female subjects with pregnancy or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note